Literature DB >> 9558090

CTLA-4 regulates tolerance induction and T cell differentiation in vivo.

T L Walunas1, J A Bluestone.   

Abstract

Cytotoxic T lymphocyte Ag-4 (CTLA-4; CD152) is an important T cell regulatory molecule. In vitro experiments have shown that the blockade of signals through CTLA-4 augments T cell expansion, while CTLA-4 cross-linking results in decreased T cell proliferation due to decreased IL-2 production. However, less is known about the role of CTLA-4 in regulating an ongoing immune response. In this study, we examined the role of CTLA-4 in the expansion, decline, tolerization, and differentiation of T cells following treatment with staphylococcal enterotoxin B (SEB). Anti-CTLA-4 treatment resulted in increased numbers of SEB-reactive T cells and blockade of subsequent tolerance induction. Further examination of the SEB-reactive cells from anti-CTLA-4-treated mice demonstrated that both the CD4+ and CD8+ Vbeta8+ T cells produced IL-4, providing evidence that not only do signals through CTLA-4 regulate T cell-tolerizing events, but they also play an important role in the differentiation of T cells in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9558090

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

Review 1.  The contributions of T-cell anergy to peripheral T-cell tolerance.

Authors:  R Lechler; J G Chai; F Marelli-Berg; G Lombardi
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

2.  Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy.

Authors:  A D Wells; M C Walsh; J A Bluestone; L A Turka
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

3.  Effect of in vivo administration of anti-CTLA-4 monoclonal antibody and IL-12 on the induction of low-dose oral tolerance.

Authors:  K S Barone; B Herms; L Karlosky; S Murray; J Qualls
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

4.  Spontaneous allograft tolerance in B7-deficient mice independent of preexisting endogenous CD4+CD25+ regulatory T-cells.

Authors:  Todd J Grazia; Robert J Plenter; An N Doan; Brian P Kelly; Sarah M Weber; Jonathan S Kurche; Susan O Cushing; Ronald G Gill; Biagio A Pietra
Journal:  Transplantation       Date:  2007-06-15       Impact factor: 4.939

5.  Mechanisms for induction of acquired host immunity by neutrophil peptide defensins.

Authors:  J W Lillard; P N Boyaka; O Chertov; J J Oppenheim; J R McGhee
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

6.  MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function.

Authors:  Nina C Zitzer; Katiri Snyder; Xiamoei Meng; Patricia A Taylor; Yvonne A Efebera; Steven M Devine; Bruce R Blazar; Ramiro Garzon; Parvathi Ranganathan
Journal:  J Immunol       Date:  2018-05-02       Impact factor: 5.422

Review 7.  The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.

Authors:  Eric M Ruderman; Richard M Pope
Journal:  Arthritis Res Ther       Date:  2005-03-16       Impact factor: 5.156

Review 8.  Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor.

Authors:  P Scheipers; H Reiser
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

9.  Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.

Authors:  Mark J Dobrzanski; Kathleen A Rewers-Felkins; Imelda S Quinlin; Khaliquzzaman A Samad; Catherine A Phillips; William Robinson; David J Dobrzanski; Stephen E Wright
Journal:  Clin Immunol       Date:  2009-09-16       Impact factor: 3.969

10.  Low concentrations of lipopolysaccharide synergize with peptides to augment human T-cell proliferation and can prevent the induction of non-responsiveness by CTLA4-Ig.

Authors:  M R Goodier; M Londei
Journal:  Immunology       Date:  2001-01       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.